亚型A1和D,以及与乌干达的莱纳卡巴维尔耐药性相关的复合HIV-1自然多态
Daniel Omoding1, Nicholas Musinguzi1, Yap Boum2
1Department of Community Health, Mbarara University of Science and Technology, Mbarara, Uganda.
The Journal of antimicrobial chemotherapy
|January 30, 2025
概括
在乌干达的HIV-1亚型A1和D中,莱纳卡巴维尔耐药性突变是罕见的. 这一发现支持莱纳卡巴维尔.
科学领域:
- 病毒学 病毒学
- 传染性疾病 传染性疾病
- 药物耐药性 药物耐药性 药物耐药性
背景情况:
- 莱纳卡帕维尔是一种新的HIV-1囊抑制剂,具有治疗多药耐药HIV-1 (MDR HIV-1) 和暴露前预防 (PrEP) 的潜力.
- 莱纳卡帕维尔的独特机制和缺乏交叉耐药性在艾滋病毒治疗中提供了显著的优势.
- 之前对lenacapavir耐药性突变的研究,如M66I和Q67H,主要集中在HIV-1亚型B.
研究的目的:
- 确定艾滋病毒-1亚型A1和D的莱纳卡巴维尔耐药性相关突变的流行率.
- 分析来自乌干达西南部的HIV-1阳性个体队列中的lenacapavir耐药性.
主要方法:
- 从乌干达抗逆转录病毒疗法 (ART) 未经治疗的成年人的血样本中分析HIV-1 Gag p24 (capsid) 序列.
- 在这些序列中研究lenacapavir耐药性突变.
主要成果:
- 在546名未服用莱纳卡巴维尔的参与者中,没有检测到与莱纳卡巴维尔耐药性相关的重大突变.
- 在1.6%的参与者中发现了包括T107A在内的轻微突变,在一个案例中,T107A持续超过三年.
- 遗传学和香农缩分析表明,观察到的囊变异性和已知的莱纳卡巴维尔耐药部位之间没有重叠.
结论:
- 这项研究表明,在乌干达,自然发生的勒纳卡巴维尔耐药性突变的患病率很低.
- 这些发现支持lenacapavir在该地区治疗和预防HIV的潜在疗效.
相关概念视频
01:10Retrovirus Life Cycles
45.6K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
45.6K
00:36Viral Mutations
32.1K
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
32.1K